Venus Remedies Receives Second PLI Disbursement for FY25

Panchkula-based Venus Remedies has received its second incentive disbursement under the Government of India’s PLI scheme for pharmaceuticals, taking the total payout to 75 percent of the incentive eligible for FY 2024–25.

The latest release confirms the company’s strong progress under the flagship policy aimed at boosting domestic drug manufacturing and reducing import dependence.

The incentive was released after Venus Remedies successfully met the required investment, production, and sales benchmarks laid out under the scheme. According to the company, the repeat disbursement reflects consistent execution and strict adherence to the performance thresholds defined by the government, reinforcing its standing as a reliable participant in the program.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

The company is among a limited group of pharmaceutical firms approved under PLI 2.0, a category focused on high-value and complex products. As a leading manufacturer of fixed-dosage injectables, Venus Remedies plans to use the incentives to scale up manufacturing capacity, integrate advanced technologies, and strengthen its presence across regulated and emerging markets.

The support is also expected to aid long-term capital investment, drive innovation-led growth, and generate employment, while contributing to the expansion and resilience of India’s pharmaceutical manufacturing base.

Saransh Chaudhary, president, global critical care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said: “The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities. These incentives will support capacity expansion, enable investments in advanced and globally competitive technologies, and deepen our contribution to a resilient and self-reliant healthcare ecosystem. As we scale responsibly, we remain aligned with national healthcare and industrial priorities, with a strong focus on quality, supply-chain security, and long-term value creation.”